dan

You were born with cells whose only job is to find and kill cancer. They're called natural killer cells. In most cancer patients, they don't show up in large enough numbers or stay active long enough to win. A drug called Anktiva changes that, and the early results are wild. Anktiva works by flipping a protein switch in your body that tells your natural killer cells to multiply faster and fight harder. Chemo poisons cancer but destroys your immune system along the way, which is why patients lose their hair, get infections, and feel wrecked. Anktiva does the opposite. Instead of poisoning everything and hoping cancer dies first, it powers up the defense system you were already born with. The FDA approved it in April 2024 for one specific type of bladder cancer. It was tested on 77 patients. In 6 out of 10 cases, all detectable signs of cancer disappeared completely. 40% of those patients stayed cancer-free for two years or more. But the number that stands out: six patients from that original group were checked 9 years later. All six are still cancer-free. From a drug that has never been used in chemotherapy. In January 2026, Saudi Arabia became the first country to approve Anktiva for lung cancer, not just bladder cancer. It's now approved in 33 countries. Sales hit $113 million last year, up 700% from the year before. The EU approved it in February 2026. Trials are running in pancreatic cancer, brain cancer, and a handful of others. The catch: the U.S. FDA has been pushing back hard. It refused to expand Anktiva's approval to additional patients with bladder cancer in May 2025. It caught the company exaggerating results on its website twice. The company paid $10.5 million to settle a lawsuit filed by investors who said leadership overpromised about how ready their factories were. The gap between 77 patients with bladder cancer and a broad cancer treatment is still enormous. (The tweet also says he's Japanese. He's not. Patrick Soon-Shiong is South African-born Chinese, grew up under apartheid, and is a billionaire who owns the LA Times and is part of the Lakers. But that's a footnote to the actual science.)